Lockheed Martin Exposure Increased

I last reviewed Lockheed Martin (LMT) in this July 19 post at which time LMT had just raised its FY2023 adjusted diluted EPS guidance to ~$27.00 – ~$27.20 from the prior ~$26.60 - ~$26.90 guidance. Based on my assessment, I increased my exposure by 50 shares in one of the 'Core' accounts within the FFJ [...]

By |September 7th, 2023|Equity Investing|Comments Off on Lockheed Martin Exposure Increased

FFJ Portfolio – August 2023

This FFJ Portfolio - August 2023 report is an overview of my recent investment activity. Relative to August 2022, the value of the FFJ Portfolio has fallen by ~$15,606 CDN and increased by ~$1,153,509 USD. The increase is attributed to my concerted effort to increase my exposure to high-quality US companies. Purchases In The FFJ [...]

By |September 1st, 2023|FFJ Portfolio Holdings|Comments Off on FFJ Portfolio – August 2023

HEICO Is Firing On All Cylinders

HEICO Corporation has two classes of common stock (HEI and HEI.a). Both classes of shares are virtually identical in all economic respects except voting rights. The difference is that each HEI share is entitled to one vote per share while each HEI.a share is entitled to a 1/10 vote per share. This post focuses on [...]

By |August 30th, 2023|Equity Investing|Comments Off on HEICO Is Firing On All Cylinders

Rollins Is Positioned For Faster Growth

In July 2022, Rollins (ROL) announced its Board had approved the company's 2023 CEO succession plan. In August 2022, ROL named a new CFO. Since such time, the quality of financial information has improved. I last reviewed ROL in this February 20, 2023 post at which time the company had just released its Q4 and [...]

By |August 26th, 2023|Equity Investing|Comments Off on Rollins Is Positioned For Faster Growth

Zoom Video Communications Is Undervalued

In late 2020, I looked at Zoom Video Communications, Inc. (ZM) and quickly determined shares were grossly overvalued. A few days ago, someone asked me for my opinion of the company. With the release of Q2 and YTD2024 results after the August 21 market close, I now revisit ZM. NOTE: ZM is NOT to be [...]

By |August 23rd, 2023|Equity Investing|Comments Off on Zoom Video Communications Is Undervalued

Agilent – Transitory Headwinds Present A Buying Opportunity

In my May 10 post, I disclose my decision to initiate a 200-share Agilent Technologies (A) position @ ~$127/share in a 'Core' account within the FFJ Portfolio. On June 9 and July 6, I acquired an additional 100 shares @ ~$115.96/share and ~$118.48/share. These purchases lowered my average cost to ~$122.35 and brought my total [...]

By |August 16th, 2023|Equity Investing|Comments Off on Agilent – Transitory Headwinds Present A Buying Opportunity

TROW Struggles To Grow

  In my August 10 guest post at Dividend Power, I explain why I have no exposure to T. Rowe Price (TROW) and why I have no intention of initiating a position. In an industry where participants are heavily dependent on Assets Under Management (AUM) and performance track record relative to peers, TROW's struggles are [...]

By |August 10th, 2023|Equity Investing|Comments Off on TROW Struggles To Grow

Broadridge Plans A More Balanced Capital Allocation In FY2024

I last reviewed Broadridge Financial Solutions (BR) in this November 29, 2022 post at which time it had recently released its Q1 2022 results. With the release of the Q4 and FY2023 results and FY2024 guidance, I take this opportunity to revisit this existing holding. Business Overview BR operates in two reportable segments, Investor Communication [...]

By |August 9th, 2023|Equity Investing|Comments Off on Broadridge Plans A More Balanced Capital Allocation In FY2024

Merck – Top 2 Selling Drugs Begin To Lose Patent Protection In 2028

In my February 8, 2021 post, I disclose a new Merck & Co (MRK) position in a 'Core' account within the FFJ Portfolio with the purchase of 300 shares @ ~$75/share. I subsequently disclosed in this May 3, 2021 post the purchase of another 100 shares @ ~$75/share. Through the automatic reinvestment of the dividend [...]

By |August 4th, 2023|Equity Investing|Comments Off on Merck – Top 2 Selling Drugs Begin To Lose Patent Protection In 2028

Added Paycom Software To The FFJ Portfolio

I have been closely monitoring Paycom Software (PAYC) in that I have been a long-term Automatic Data Processing (ADP) and Paychex (PAYX) shareholder. I was tempted to initiate a PAYC position in early May. However, I opted to wait until the release of Q2 2023 results in early August and acquired Blackstone (BX), BlackRock (BLK), [...]

By |August 3rd, 2023|Equity Investing|Comments Off on Added Paycom Software To The FFJ Portfolio
Go to Top